Analysts Set Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Price Target at $36.60

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) has been assigned a consensus recommendation of “Buy” from the six analysts that are currently covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $37.17.

KNSA has been the topic of several research reports. Wedbush reiterated an “outperform” rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th. Citigroup started coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $40.00 price objective on the stock.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals news, CFO Mark Ragosa sold 36,372 shares of Kiniksa Pharmaceuticals stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $22.25, for a total transaction of $809,277.00. Following the transaction, the chief financial officer now directly owns 22,958 shares of the company’s stock, valued at $510,815.50. The trade was a 61.30 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock in a transaction on Monday, February 10th. The stock was sold at an average price of $19.57, for a total transaction of $273,980.00. Following the transaction, the chief operating officer now directly owns 81,975 shares in the company, valued at $1,604,250.75. This represents a 14.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 73,423 shares of company stock valued at $1,541,812 in the last three months. 54.57% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

A number of hedge funds have recently bought and sold shares of KNSA. Wellington Management Group LLP purchased a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter valued at $1,192,000. JPMorgan Chase & Co. purchased a new stake in Kiniksa Pharmaceuticals during the third quarter worth about $4,997,000. Segall Bryant & Hamill LLC bought a new stake in Kiniksa Pharmaceuticals in the third quarter worth about $675,000. Parkman Healthcare Partners LLC boosted its stake in Kiniksa Pharmaceuticals by 16.7% in the third quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company’s stock valued at $18,874,000 after acquiring an additional 108,102 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Kiniksa Pharmaceuticals during the 4th quarter valued at approximately $355,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Trading Up 2.0 %

KNSA stock opened at $22.61 on Thursday. The stock has a 50-day moving average price of $19.99 and a 200-day moving average price of $22.16. Kiniksa Pharmaceuticals has a 1-year low of $16.56 and a 1-year high of $28.15. The firm has a market cap of $1.64 billion, a PE ratio of -161.49 and a beta of 0.48.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business had revenue of $122.50 million during the quarter, compared to the consensus estimate of $123.42 million. During the same period last year, the business posted $0.35 earnings per share. The business’s revenue was up 46.9% on a year-over-year basis. On average, analysts forecast that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current year.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.